Asunto(s)
Infecciones por Helicobacter , Helicobacter pylori , Cobertura del Seguro , Neoplasias Gástricas , Humanos , Neoplasias Gástricas/epidemiología , Infecciones por Helicobacter/tratamiento farmacológico , Infecciones por Helicobacter/epidemiología , Japón/epidemiología , Incidencia , Masculino , Femenino , Persona de Mediana Edad , Anciano , Adulto , Antibacterianos/uso terapéuticoAsunto(s)
Esofagitis , Inhibidores del Factor Xa , Piridinas , Tiazoles , Humanos , Piridinas/efectos adversos , Piridinas/uso terapéutico , Esofagitis/inducido químicamente , Inhibidores del Factor Xa/efectos adversos , Inhibidores del Factor Xa/uso terapéutico , Tiazoles/efectos adversos , Fibrilación Atrial/tratamiento farmacológico , Fibrilación Atrial/inducido químicamente , Masculino , Femenino , AncianoAsunto(s)
Isquemia Encefálica , Accidente Cerebrovascular Isquémico , Enfermedad de Moyamoya , Accidente Cerebrovascular , Humanos , Accidente Cerebrovascular Isquémico/diagnóstico por imagen , Accidente Cerebrovascular Isquémico/etiología , Accidente Cerebrovascular/complicaciones , Isquemia Encefálica/diagnóstico por imagen , Isquemia Encefálica/etiología , Enfermedad de Moyamoya/complicacionesAsunto(s)
Infecciones por Helicobacter , Helicobacter pylori , Humanos , Amoxicilina/efectos adversos , Claritromicina/efectos adversos , Antibacterianos/efectos adversos , Factores de Riesgo , Infecciones por Helicobacter/tratamiento farmacológico , Quimioterapia Combinada , Inhibidores de la Bomba de Protones/efectos adversos , Resultado del TratamientoRESUMEN
BACKGROUND: Some patients find it difficult to discontinue proton pump inhibitors (PPIs). Unlike the 13 C-urea breath test (UBT), the stool antigen test (SAT), particularly when domestically produced kits are used, may be less likely to yield false-negative results. METHODS: This prospective study included a convenience series of 35 healthy Japanese subjects. Based on a statistical calculation, acceptable numbers of subjects were considered at least 21 and 11 with and without Helicobacter pylori (H. pylori) infection, respectively. The H. pylori infection was determined using the UBT or rapid urease test. SATs were performed with three novel domestically produced kits (the rapid immunochromatography tests Quick Navi™-H. pylori [Navi™] and Quick Chaser® H. pylori [Chaser®], and the bioluminescent enzyme immunoassay test BLEIA® 'EIKEN' H. pylori Antigen [BLEIA®]) before and after oral PPI administration (30 mg lansoprazole once daily for 14 days). For each kit, the sensitivities and specificities were calculated and compared before and after PPI administration. Furthermore, the cutoff index (COI) values of BLEIA® before and after PPI administration were compared in H. pylori-infected subjects. RESULTS: H. pylori infection was detected in 68.6% (24/35) of the included subjects. The sensitivities and specificities before versus after PPI administration were as follows: 79.2% (19/24) and 100.0% (11/11) versus 75.0% (18/24) and 100.0% (11/11) for Navi™, respectively (p = 1); 87.5% (21/24) and 100.0% (11/11) versus 75.0% (18/24) and 100.0% (11/11) for Chaser®, respectively (p = .371); 100.0% (24/24) and 100.0% (11/11) versus 95.8% (23/24) and 100.0% (11/11) for BLEIA®, respectively (p = 1). The median COI values of BLEIA® before and after PPI administration were 1389.0 and 3207.25, respectively (p = .0839). CONCLUSIONS: In stool specimens, H. pylori antigenicity is maintained even during PPI use. SAT using a bioluminescent enzyme immunoassay is particularly recommended because of its extremely high sensitivity.